Key result
Novel clinical-imaging score differentiates ARVC from athlete's heart with ~93% diagnostic accuracy.
Why the study?
The 2010 Task Force Criteria have not been tested to differentiate ARVC from athlete's heart, and several criteria are unavailable or subject to interobserver variability in routine practice.
Does a novel diagnostic score integrating atrial dimensions and readily available clinical parameters accurately differentiate ARVC from the athlete's heart compared to standard criteria?
Case-Control (n=63)
No
Does a novel diagnostic score integrating atrial dimensions and readily available clinical parameters accurately differentiate ARVC from the athlete's heart compared to standard criteria?
A novel diagnostic score incorporating atrial dimensions and NT-proBNP provides high diagnostic accuracy for differentiating ARVC from the athlete's heart using routine clinical parameters.
Answers are grounded in this paper and cite their sources.
May support ARVC differentiation from athlete's heart using routine parameters; leaves open prospective validation before clinical adoption.
Objective: The 2010 Task Force Criteria (TFC) have not been tested to differentiate ARVC from the athlete’s heart. Moreover, some criteria are not available (myocardial biopsy, genetic testing, morphology of ventricular tachycardia) or subject to interobserver variability (right ventricular regional wall motion abnormalities) in clinical practice. We hypothesized that atrial dimensions are useful and robust to differentiate between both entities and proposed a new diagnostic score based upon readily available parameters including echocardiographic atrial dimensions. Methods: In this observational study, 21 patients with definite ARVC were matched for age, gender and body mass index to 42 athletes. Based on ROC analysis, the following parameters were included in the score: indexed right/left atrial volumes ratio (RAVI/LAVI ratio), NT-proBNP, RVOT measurements (PLAX and PSAX BSA-corrected), tricuspid annular motion (TAM), precordial TWI and depolarization abnormalities according to TFC. Results: ARVC patients had a higher RAVI/LAVI ratio (1.76 ± 1.5 vs. 0.87 ± 0.2, p < 0.001), lower right ventricular function (fac: 29 ± 10.1 vs. 42.2 ± 5%, p < 0.001; TAM: 19.8 ± 5.4 vs. 23.8 ± 3.8 mm, p = 0.001) and higher serum NT-proBNP levels (345 ± 612 vs. 48 ± 57 ng/L, p < 0.001). Our score showed a good performance, which is comparable to the 2010 TFC using those parameters, which are available in routine clinical practice (AUC93%, p < 0.001 (95%CI 0.874–0.995) vs. AUC97%, p < 0.001 (95%CI 0.93–1.00). A score of 6/12 points yielded a specificity of 91% and an improved sensitivity of 67% for ARVC diagnosis as compared to a sensitivity of 41% for the abovementioned readily available 2010 TFC. Conclusions: ARVC patients present with significantly larger RA compared to athletes, resulting in a greater RAVI/LAVI ratio. Our novel diagnostic score includes readily available clinical parameters and has a high diagnostic accuracy to differentiate between ARVC and the athlete’s heart.
No takes yet. Share an insight, caveat, or question.
Rossi et al. (2021) conducted a case-control in Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) vs. Athlete's Heart (n=63). Novel diagnostic score (integrating RAVI/LAVI ratio, NT-proBNP, RVOT, TAM, and ECG abnormalities) vs. 2010 Task Force Criteria was evaluated on Diagnostic accuracy (Area Under the Curve) to differentiate ARVC from athlete's heart (AUC 93%, 95% CI 0.874-0.995, p=<0.001). A novel diagnostic score integrating atrial dimensions and routine clinical parameters yielded a high diagnostic accuracy to differentiate ARVC from athlete's heart.
Synapse has enriched 10 related papers. Consider them for comparative context: